Plasma or serum samples: measurements of cardiac troponin T and of other analytes compared.

Conflicting data in the literature concern possible differences in the immunochemical measurement of cardiac troponins, either in plasma or in serum. In order to address this specific point, 96 serum and heparin-plasma pairs were obtained for cardiac marker measurement [cardiac troponin T (cTnT); myoglobin (Myo) and creatine kinase-MB isoenzyme (CK-MB)]; 29 additional "common" analytes were measured in 77 such samples. The cardiac markers were measured by electrochemiluminescence (Elecsys 2010, Roche); the other analytes by established automated methods (Modular, Roche). Mean plasma/serum ratios for cTnT (0.95), creatine kinase-MB (1.01) and myoglobin (0.99) were comparable with those of the 29 common analytes (interval of means 0.83-1.05). The distribution of the plasma-serum differences also showed similarities between cardiac markers and other analytes. A few outlier plasma-serum differences (3-5%) were measured for both categories of analytes. Addition of heparin to serum (51 samples) caused decreased cTnT (mean ratio 0.92). In 3 of 51 such samples the cTnT decrease was more marked, but in a second sample from the same subjects (1 week later) such a prominent, heparin-induced loss of cTnT no longer appeared. In conclusion, plasma-serum differences in immuno-reactive cTnT compare with those observed for other analytes. In occasional heparin-plasma samples immunochemical measurement of cTnT may give exceptionally low values. However, in our sample group of 96 patients (cTnT lower or higher than the cut-off in, respectively, 24 and 72 patients), no misclassification occurred if plasma instead of serum cTnT values were considered.     

Aortic root dilation in associated with the reduction in capillary density observed at nailfold capillaroscopy in SSc patients

Clinical Rheumatology - Systemic sclerosis (SSc) is an autoimmune disease characterized by endothelial dysfunction and fibroblasts activation. Microvascular disease may be easily observed by means...     

Optimization of 3D ZnO brush-like nanorods for dye-sensitized solar cells

In a dye-sensitized solar cell (DSSC) the amount of adsorbed dye on the photoanode surface is a key factor that must be maximized in order to obtain enhanced DSSC performance. In this study 3D ZnO nanostructures, named brush-like, are demonstrated as alternative photoanodes. In these structures, long ZnO nanorods are covered with a metal–organic precursor, known as a layered-hydroxide zinc salt (LHZS), which is subsequently converted to crystalline ZnO using two-step annealing. The LHZS is able to easily grow on any surface, such as the ZnO nanorod surface, without needing the assistance of a seed-layer. Brush-like structures synthesized using different citrate concentrations in the growth solutions and different annealing conditions are characterized and tested as DSSC photoanodes. The best-performing structure reported in this study was obtained using the highest citrate concentration (1.808 mM) and the lowest temperature annealing condition in an oxidative environment. Conversion efficiency as high as 1.95% was obtained when these brush-like structures were employed as DSSC photoanodes. These results are extremely promising for the implementation of these innovative structures in enhanced DSSCs, as well as in other applications that require the maximization of surface area exposed by ZnO or similar semiconductors, such as gas- or bio-sensing or photocatalysis.

Optimized 3D ZnO brush-like nanorods showing large surface area are presented as the photoanode in enhanced high-current-density DSSCs.     

New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential

The antiangiogenic effects of three novel anilinoquinazoline derivatives were studied with the aim to find new multi-kinase inhibitors as anticancer agents. The compounds are characterized by dioxolane, dioxane and dioxepine rings and bear the same aniline substituent in 4 position as Vandetanib, known antiangiogenic agent. The in vitro assays were carried out on human umbilical vein endothelial cells (HUVECs), whereas in vivo angiogenesis was evaluated by means of Matrigel plug assay. The results showed that these compounds exert, even though to different extents, antiangiogenic activity affecting the various step of the process that leads to the formation of new blood vessels. At high concentrations they induced antiproliferative effects, whereas at non-cytotoxic concentrations they inhibited cell migration and the formation of tubular structures in Matrigel. In in vitro assays the dioxolane derivative 1 was more effective than Vandetanib. Indeed, it inhibited the effects induced by exogenous VEGF and FGF-2 on both cell proliferation and morphogenesis, whereas Vandetanib was completely ineffective. Moreover, all the compounds, as Vandetanib, counteracted the FGF-2-induced increase in the hemoglobin content in the Matrigel plugs. Our results showed that all the three novel derivatives possess both in vitro and in vivo antiangiogenic activity, with compound 1 more effective than Vandetanib to inhibit in vitro angiogenesis induced by exogenous cytokines.